of prostate cancer diagnosis and prognosis requires either narrowing the risk group by identifying
new genetic
Shnayder, Natalia A.,
Grechkina, Violetta V.,
Trefilova, Vera V.,
Efremov, Ilya S.,
Dontceva, Evgenia A.,
Narodova, Ekaterina A.,
Petrova, Marina M.,
Soloveva, Irina A.,
Tepnadze, Liia E.,
Reznichenko, Polina A.,
Al-Zamil, Mustafa,
Altynbekova, Gulnara I.,
Strelnik, Anna I.,
Nasyrova, Regina F. (2023) -MetS. These metabolic biomarkers may provide the key to the development of a
new multidisciplinary personalized strategy
Sufianov, Albert,
Beilerli, Aferin,
Kudriashov, Valentin,
Ilyasova, Tatiana,
Wenjie, Bu,
Beylerli, Ozal (2023) delivery systems and lead to improvement of the efficiency of many
new biopharmaceuticals. Designing
Gareev, Ilgiz,
de Jesus Encarnacion Ramirez, Manuel,
Goncharov, Evgeniy,
Ivliev, Denis,
Shumadalova, Alina,
Ilyasova, Tatiana,
Wang, Chunlei (2023) the expression and maturation of
new ncRNAs and the conservation of ncRNAs in evolution. © 2023 The Authors
Gareev, Ilgiz,
Beylerli, Ozal,
Tamrazov, Rasim,
Ilyasova, Tatiana,
Shumadalova, Alina,
Du, Weijie,
Yang, Baofeng (2023) the primary research pathways in the development of
new anti-cancer medications, with a particular focus
Chen, P.,
Yu, Y.,
Su, S.,
Du, Z.,
Cai, B.,
Sun, X.,
Chattipakorn, N.,
Samorodov, A.V.,
Pavlov, V.N.,
Tang, Q.,
Cho, W.-J.,
Liang, G. (2023) in lung tissues. Thus, compound 39 could serve as a
new lead structure for the development of anti